TLA technology & targeted complete NGS of genes and gene fusions in leukemia

In this webinar, we dive into the relevance of TLA technology for the detection of gene fusions and breakpoint sequences. In demonstrating the unique capabilities of TLA, we draw on multiple case studies such as the work performed by Roland Kuiper from Princess Maxima Center for Pediatric Oncology. In the second part of this joint webinar, Beat Schafer (University Children’s Hospital Zurich) presents our collaborative work and explains how the detected breakpoint sequences can also be used as sensitive MRD marker.

Outline of this talk:

  • Principle of TLA technology
  • Detection of gene fusions
  • Detection of breakpoint sequences
  • Use of breakpoint sequences as MRD marker
  • CAR-T cell validation
  • Conclusions


© 2012-2021 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.
We use cookies for website analysis and marketing. By visiting and using our website you accept these cookies.